Compare LAB & CION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LAB | CION |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Finance/Investors Services |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.9M | 527.0M |
| IPO Year | 2011 | N/A |
| Metric | LAB | CION |
|---|---|---|
| Price | $1.27 | $9.63 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 2 | 1 |
| Target Price | $1.35 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 1.5M | 437.3K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 15.31% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.49 |
| Revenue | $169,737,000.00 | ★ $244,923,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $19.78 |
| Revenue Growth | ★ 79.77 | N/A |
| 52 Week Low | $0.92 | $8.51 |
| 52 Week High | $2.14 | $12.71 |
| Indicator | LAB | CION |
|---|---|---|
| Relative Strength Index (RSI) | 39.35 | 46.03 |
| Support Level | $1.46 | $9.43 |
| Resistance Level | $1.72 | $10.17 |
| Average True Range (ATR) | 0.09 | 0.19 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 10.20 | 24.23 |
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.